Benitec Biopharma Inc expected to post a loss of 55 cents a share - Earnings Preview

Benitec Biopharma

08/11/2024 16:48

* Benitec Biopharma Inc  BNTC.OQ   BNTC.O  is expected
to show no
change in quarterly revenue when it reports  results on November
11 (estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Benitec Biopharma Inc is
for a
loss of 55 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Benitec
Biopharma
Inc is $20.00​, above​ its last closing price of $10.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.53       -0.49      -1.32     Missed  -170.4
 Mar. 31 0001  -0.78       -0.78      -1.64     Missed  -110
 Dec. 31 2023  -0.39       -0.39      -2.64     Missed  -576.9
                                                        ​
 Sep. 30 2023  -0.51       -0.51      -2.76     Missed  -441.2
 ​​Jun.                    -3.23      -2.83     Beat    12.3
 30 2023                                                
 Mar. 31 2023  -3.40       -3.40      -2.72     Beat    20​
 Dec. 31 2022  -1.87       -1.87      -3.40     Missed  -81.8
 Sep. 30 2022  -3.21       -3.14      -7.99     Missed  -154.1
 This summary was machine generated November 8 at 16:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)